Severe Pulmonary Mycobacterium abscessus Cases Due to Co-Infection with Other Microorganisms Well Treated by Clarithromycin and Sitafloxacin in Japan

Takano, Kazuki; Shimada, Daishi; Kashiwagura, Shota; Kamioka, Yasuhiro; Hariu, Maya; Watanabe, Yuji; Seki, Masafumi

doi:10.2147/imcrj.s321969

Cited by 11 publications

(13 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Analysis of its mechanism may suggest that clarithromycin has an anti-inflammatory effect. When clarithromycin enters the body, it can penetrate the cell wall of bacteria, inhibit the synthesis of bacterial ribosomal 50 S subunit protein, and finally inhibit the production of bacteria to achieve the purpose of anti-inflammatory [ 11 ]. After the inflammation is reduced or eliminated, the erythema fades, the papules subside, and the skin condition significantly improves.…”

Section: Related Research and Analysismentioning

confidence: 99%

[Retracted] Analysis of the Effect of DPL Combined with Clarithromycin in the Therapy and Improvement of Rosacea

Yan

Peng

2022

Contrast Media & Molecular Imaging

View full text Add to dashboard Cite

Rosacea is a chronic inflammatory skin disease with a high incidence, and it leads to negative emotions such as inferiority complex, increased psychological pressure, and a greatly reduced quality of life. In order to investigate the clinical efficacy of DPL combined with clarithromycin in the treatment and improvement of rosacea. 86 patients with rosacea were selected and randomly divided into the control group and study group according to the random number table method. The results show that the combination of DPL and clarithromycin in the treatment of rosacea patients can effectively improve the clinical symptoms of patients, improve the therapeutic effect, and the incidence of adverse reactions is low, which ensures that the patients have a good prognosis, which is worthy of clinical application.

show abstract

Section: Related Research and Analysismentioning

confidence: 99%

[Retracted] Analysis of the Effect of DPL Combined with Clarithromycin in the Therapy and Improvement of Rosacea

Yan

Peng

2022

Contrast Media & Molecular Imaging

View full text Add to dashboard Cite

show abstract

“…Importantly, sitafloxacin exhibits antibacterial activity against M. tuberculosis and M. avium both in vitro and in vivo (Tomioka et al, 1999;Sato et al, 2003;Asakura et al, 2019). Cases of M. abscessus infection successfully treated with a drug combination that included sitafloxacin were reported (Oka et al, 2021;Takano et al, 2021). The efficacy of sitafloxacin alone in treating M. abscessus infections, however, remains to be evaluated.…”

Section: Discussionmentioning

confidence: 99%

“…massiliense ) activity that was comparable to clarithromycin, and which tended to be greater than moxifloxacin albeit without reaching statistical significance. Notably, five severe M. abscessus cases recently treated with a combination of clarithromycin and sitafloxacin achieved good clinical and microbiological outcomes ( Takano et al, 2021 ).…”

Section: Discussionmentioning

confidence: 99%

“…Sitafloxacin is an oral quinolone, which exhibits excellent antibacterial activity by simultaneously inhibiting DNA gyrase and topoisomerase IV in a broad range of bacteria including mycobacteria (Tomioka et al, 1999;Sato et al, 2003;Amano et al, 2016;Nakajima et al, 2016;Asakura et al, 2019;Kamada et al, 2021). Reports of the successful treatment of cases of M. abscessus-associated pneumonia with drug combinations that included sitafloxacin have provoked a recent interest in using sitafloxacin for treating M. abscessus infections (Oka et al, 2021;Takano et al, 2021). Information concerning the anti-M. abscessus activity of sitafloxacin is limited, however.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Sitafloxacin Expresses Potent Anti-Mycobacterium abscessus Activity

Guo

Zhao

et al. 2022

Front. Microbiol.

View full text Add to dashboard Cite

Therapeutic options for treating Mycobacterium abscessus infections are extremely limited; quinolones are important. The in vitro anti-M. abscessus activities of nine quinolones, emphasizing sitafloxacin, were investigated. Antimicrobial susceptibility testing was performed on 10 non-tuberculous mycobacterium reference strains and 194 clinical, M. abscessus isolates. The activity of sitafloxacin against intracellular M. abscessus residing within macrophages was also evaluated. A checkerboard assay was conducted to determine synergy between sitafloxacin and 10 clinically important antibiotics. Among the nine quinolones tested, sitafloxacin exhibited the greatest anti-M. abscessus activity with MIC50 and MIC90 of 1 and 2 mg/L, respectively. Sitafloxacin exerted a bacteriostatic effect on M. abscessus and inhibited the intracellular growth of M. abscessus at concentrations equivalent to clarithromycin. No antagonism between sitafloxacin and 10 clinically important anti-M. abscessus antibiotics was evident. In summary, sitafloxacin exhibited a significant advantage relative to other quinolones in inhibiting the growth of M. abscessus in vitro, suggesting the potential inclusion of sitafloxacin in new strategies to treat M. abscessus infections.

show abstract

“…49,50 In the case of CF patients, M. abscessus infection may also be exacerbated by polybacterial lung infections with other microorganisms, such as P. aeruginosa and/or S. aureus. 46 In this context of coinfection, M. abscessus would be missed in the absence of effective microbiological surveillance, whereas it is of great importance to accurately detect its presence in patient's sputum in order to adapt the antimicrobial treatment. 22,49 Toward the generation of new antibacterial leads, the CyC analogues are not only nontoxic for mammalian cells, but above all represent a novel class of selective and efficient multitarget inhibitors leading to the arrest of M. abscessus extracellular and/ or intracellular growth through the inhibition of various mycobacterial enzymes involved in important physiological processes.…”

Section: ■ Discussionmentioning

confidence: 99%

Synthesis and Biological Characterization of Fluorescent Cyclipostins and Cyclophostin Analogues: New Insights for the Diagnosis of Mycobacterial-Related Diseases

et al. 2022

View full text Add to dashboard Cite

Patients with cystic fibrosis (CF) have a significantly higher risk of acquiring nontuberculous mycobacteria infections, predominantly due to Mycobacterium abscessus, than the healthy population. Because M. abscessus infections are a major cause of clinical decline and morbidity in CF patients, improving treatment and the detection of this mycobacterium in the context of a polymicrobial culture represents a critical component to better manage patient care. We report here the synthesis of fluorescent Dansyl derivatives of four active cyclipostins and cyclophostin analogues (CyCs) and provide new insights regarding the CyC's lack of activity against Gram-negative and Gram-positive bacteria, and above all into their mode of action against intramacrophagic M. abscessus cells. Our results pointed out that the intracellularly active CyC accumulate in acidic compartments within macrophage cells, that this accumulation appears to be essential for their delivery to mycobacteria-containing phagosomes, and consequently, for their antimicrobial effect against intracellular replicating M. abscessus, and that modification of such intracellular localization via disruption of endolysosomal pH strongly affects the CyC accumulation and efficacy. Moreover, we discovered that these fluorescent compounds could become efficient probes to specifically label mycobacterial species with high sensitivity, including M. abscessus in the presence several other pathogens like Pseudomonas aeruginosa and Staphylococcus aureus. Collectively, all present and previous data emphasized the therapeutic potential of unlabeled CyCs and the attractiveness of the fluorescent CyC as a potential new efficient diagnostic tool to be exploited in future diagnostic developments against mycobacterial-related infections, especially against M. abscessus.

show abstract

Severe Pulmonary Mycobacterium abscessus Cases Due to Co-Infection with Other Microorganisms Well Treated by Clarithromycin and Sitafloxacin in Japan

Cited by 11 publications

References 21 publications

[Retracted] Analysis of the Effect of DPL Combined with Clarithromycin in the Therapy and Improvement of Rosacea

[Retracted] Analysis of the Effect of DPL Combined with Clarithromycin in the Therapy and Improvement of Rosacea

Sitafloxacin Expresses Potent Anti-Mycobacterium abscessus Activity

Synthesis and Biological Characterization of Fluorescent Cyclipostins and Cyclophostin Analogues: New Insights for the Diagnosis of Mycobacterial-Related Diseases

Contact Info

Product

Resources

About